The FDA has required Ampio Pharmaceuticals to conduct a new clinical study for Ampion in knee osteoarthritis patients to support its marketing application. A special protocol assessment that will expand the study from 150 to 300 patients is anticipated.
Ampio asked by FDA for new trial of knee osteoarthritis therapy
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.